**PREVAIL Summary**

PREVAIL began during the worst outbreak of Ebola the world had ever seen, in an extremely resource-limited part of the world lacking basic health care infrastructure, as well as any clinical research capacity. In just 2 short years, Prevail has launched four complex clinical research trials to study the treatment, prevention and natural history of Ebola. More than 4000 Ebola patients, survivors and heathy volunteers are participating in these trials. Sustainable infrastructure including renovations at four clinical research sites, state-of-the-art laboratories, and an eye clinic are staffed by more than 150 Liberian professional and administrative personnel who have been trained and mentored to perform the day-to-day clinical research functions independently. Preliminary results of trials have been presented at international conferences and multiple manuscripts have been published in peer reviewed professional journals. Data from PREVAIL I has been used to support the expanded access of an Ebola vaccine to be administered to contacts if there is another incidence of Ebola. Expanded access for ZMapptm is expected in the near future due to the results of the PREVAIL II trial.

The stakeholders of PREVAIL met in April 2016 to formulate their strategy for the next 5 years. They built consensus around the following:



Outcomes of this project are likely to: 1) identify vaccines and treatments against EVD, 2) develop resources to detect, prevent & treat EVD, and perhaps other diseases, before they cross the borders of the US, expand our understanding of the sequelae of EVD, and 3) promote good clinical research practices throughout the West Africa.

PREVAIL began its work at unprecedented speed. The Phase 1 PREVAIL protocol took just 4 months from concept (October 2014) to launch (an activity that usually takes about 2 years). Although PREVAIL is implementing a strategic change agenda to move away from emergency response and build an on-going research enterprise, PREVAIL continues to initiate Ebola clinical research protocols in an urgent manner due to the fact that the opportunity to conduct research on people with detectable virus in reservoirs is quickly dwindling.

# Bibliography

Manuscripts

Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey Jr RT. [*Design of a randomized controlled trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM study*](https://evdpartners.org/Docs/Publications_and_Presentations/papers/prevail2/Dodd-JInfectDis-2016.pdf). J Infect Dis 2016; 213:1906-1913. <http://jid.oxfordjournals.org/content/213/12/1906.long>

Doe-Anderson J, Baseler B, Driscoll P, Johnson M, Lysander J, McNay L, Njoh WS, Smolskis M, Wehrlen L, Zuckerman J for the PREVAIL I study group. [*Beating the odds: successful establishment of a phase II/III clinical research trial in resource-poor Liberia during the largest-ever Ebola outbreak*](https://evdpartners.org/Docs/Publications_and_Presentations/papers/prevail1/Doe-Anderson-ContempClinTrials-2016.pdf). Contemp Clin Trials 2016; 4: 68-73. <http://www.sciencedirect.com/science/article/pii/S2451865415>

Kennedy SB, Neaton JD, Lane HC, Kieh MW, Massaquoi MB, Touchette NA, Nason MC, Follmann DA, Boley FK, Johnson MP, Larson G, Kateh FN, Nyenswah TG. [*Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges*](https://evdpartners.org/Docs/Publications_and_Presentations/papers/prevail1/Kennedy-ClinTrials-2016.pdf). Clin Trials 2016; 13(1):49-56. <http://ctj.sagepub.com/content/13/1/49.long>

Massaquoi MBF, Kennedy SB, Tegli JK, Bolay FK, Kateh FN. [*Fostering collaboration on post-Ebola clinical research in Liberia (letter to editor)*](https://evdpartners.org/Docs/Publications_and_Presentations/papers/prevail/Massaquoi-Lancet-2016.pdf). The Lancet 2016; e239. [http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(15)00323-X.pdf](http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X%2815%2900323-X.pdf)

PREVAIL II Writing Group (Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhuas Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D). [*A randomized, controlled trial of ZMapp for Ebola virus infection*](https://evdpartners.org/Docs/Publications_and_Presentations/papers/prevail2/PREVAILIIgroup-NEnglJMed-2016.pdf). N Engl J Med 2016; 375:1448-56. <http://www.nejm.org/doi/full/10.1056/NEJMoa1604330#t=article>

Presentations

8th International Symposium on Filoviruses, Antwerp, Belgium, 12-15 September 2016

Davey RT, PREVAIL I: a randomized controlled safety and immunogenicity trial of two different vaccines against Ebola virus -- [Slides](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-Filoviruses%5CDavey-Filoviruses-2016.pdf)

Logue J, Tuznik K, Follman D, Grandits G, Marchand J, Reilly C, Nason MC, Stavale EJ, Olinger GG, Pettitt J, Weedor Kpayieli C, Bolay FK, Hensley LE, A comparison between enzyme-linked immunosorbent assays for detection of antibodies to Ebola virus GP -- [Poster](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-Filoviruses%5CLogue-Filoviruses-2016.pdf)

Webinar: Emerging diseases in ophthalmology: Ebola and Zika viruses, 17 August 2016

Eghrari A, Bishop R, Ebola-associated eye disease -- [Slides](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-Webinar%5CEghrari-Webinar-2016.pdf)

2nd African Conference on Emerging Infectious Diseases and Biosecurity 2016, Lagos, Nigeria, July 2016

Franklin K, Tamba S, Shannon MM, Sumbo LT, Kenyen NM, Kpoto R, Badio M, A medical care referral model for research participants in a resource-limited setting: a step by step guide to the PREVAIL III referral scheme -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-2ndAfrica%5CFranklin-2ndAfrica-2016-abstract.pdf) | [Poster](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-2ndAfrica%5CFranklin-2ndAfrica-2016-poster.pptx)

PREVAIL I Study Group, PREVAIL I: a randomized controlled safety and immunogenicity trial of two different vaccines against Ebola virus -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-2ndAfrica%5CPrevailI-2ndAfrica-2016-abstract.pdf)

Association for Research in Vision and Ophthalmology Meeting (ARVO 2016), Seattle, Washington, USA, 1-5 May 2016

Bishop RJ, Eghrari AO, Brady C, Ray V, Reilly CS, Ferris F, Cunningham D, Guizie E, Fallah M, Expanding the spectrum of Ebola-associated eye disease: a summary of ocular findings in a large cohort of Ebola survivors -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-ARVO%5CBishop-ARVO-2016-abstract.pdf) | [Slides](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-ARVO%5CBishop-ARVO-2016-slides.pdf)

Eghrari A, Bishop R, Brady C, Burkholder B, Ray V, Diagnostic, medical and surgical capacity building in the setting of Ebola-associated eye disease -- [Slides](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-ARVO%5CEghrari2-ARVO-2016-slides.pdf)

Eghrari AO, Bishop RJ, Brady CJ, Ray V, Fallah M, Cunningham D, Reilly CS, Ferris FL, Larbelee J, Clinical characterization of Ebola-associated eye disease with spectral domain optical coherence tomography -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-ARVO%5CEghrari-ARVO-2016-abstract.pdf) | [Poster](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-ARVO%5CEghrari-ARVO-2016-poster.pdf)

Vahedi S, Eghrari AO, Bishop RJ, Brady CJ, Reilly CS, Ferris FL, Larbelee J, Fallah M, Implementation and assessment of visual acuity screening of Ebola Virus Disease survivors utilizing the Peek Vision smartphone platform -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-ARVO%5CVahedi-ARVO-2016-abstract.pdf) | [Poster](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-ARVO%5CVahedi-ARVO-2016-poster.pdf)

West African Sub-Regional Conference on Vaccine and Treatment Trials, Freetown, Sierra Leone, May 2016

Franklin K, Tamba S, Shannon MM, Sumbo LT, Kenyen NM, Kpoto R, Badio M, A medical care referral model for research participants in a resource-limited setting: a step by step guide to the PREVAIL III referral scheme -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-WestAfrica%5CFranklin-WestAfrica-2016.pdf)

37th Annual Meeting of the Society for Clinical Trials, Montreal, Quebec, Canada, May 2016

Neaton JD, Lessons from PREVAIL I, a phase 2/3 vaccine trial to prevent Ebola virus disease in Liberia (invited talk) -- [Slides](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-SCT%5CNeaton-SCT-2016-slides.pptx) | [Announcement](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-SCT%5CNeaton-SCT-2016-announcement.pdf)

American Academy of Neurology Annual Meeting (AAN 2016), Vancouver, BC, Canada, April 2016

Bowen L, Smith B, Steinbach S, Billioux B, Summers A, Azodi S, Ohayon J, Schindler M, Nath A for the Prevail III study group, Survivors of Ebola virus disease have persistent neurological deficits -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5CBowen-AAN-2016-abstract.pdf) | [Slides](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5CBowen-AAN-2016-slides.pptx)

Conference on Retroviruses and Opportunistic Infections (CROI) 2016, Boston, Massachusetts, February 2016

Bolay F, A randomized controlled trial of the safety and immunogenicity of two ebola vaccines -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-CROI%5CBolay-CROI-2016-abstract.pdf) | [Slides](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-CROI%5CBolay-CROI-2016-slides.mp3)

Davey RT, PREVAIL II: a randomized controlled trial of ZMapp™ in acute ebola virus infection -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-CROI%5CDavey-CROI-2016.pdf) | [Slides](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-CROI%5CDavey-CROI-2016-slides.pptx)

Fallah M, A cohort study of survivors of ebola virus infection in Liberia (PREVAIL III) -- [Abstract](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-CROI%5CFallah-CROI-2016-abstract.pdf) | [Slides](file:///%5C%5Cniaid-fas2.niaid.nih.gov%5CDocs%5CPublications_and_Presentations%5Cpresentations%5C2016-CROI%5CFallah-CROI-2016-slides.pdf)